Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland. The company's lead pivotal-stage product candidate, Eptinezumab, a monoclonal antibody inhibiting calcitonin gene-related peptide, which is in Phase III pivotal trials for the prevention of migraine. Its product candidate pipeline also includes ALD1910, a preclinical monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide-38; and Clazakizumab, that has completed two Phase 2b clinical trials designed to block the pro-inflammatory cytokine IL-6. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone425-205-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.62 million
Profitability
Miscellaneous
Employees193
OptionableOptionable
Alder Biopharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions
What is Alder Biopharmaceuticals' stock symbol?
Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."
How were Alder Biopharmaceuticals' earnings last quarter?
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) announced its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.01. View Alder Biopharmaceuticals' Earnings History.
When is Alder Biopharmaceuticals' next earnings date?
What price target have analysts set for ALDR?
13 brokers have issued 12-month price objectives for Alder Biopharmaceuticals' shares. Their forecasts range from $15.00 to $30.00. On average, they expect Alder Biopharmaceuticals' share price to reach $22.0909 in the next twelve months. This suggests a possible upside of 54.3% from the stock's current price. View Analyst Price Targets for Alder Biopharmaceuticals.
What is the consensus analysts' recommendation for Alder Biopharmaceuticals?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alder Biopharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alder Biopharmaceuticals.
What are Wall Street analysts saying about Alder Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Alder Biopharmaceuticals stock:
- 1. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (2/12/2019)
- 2. Mizuho analysts commented, "We applied a weighted average valuation methodology to Alder using DCF and EV/Sales under assumptions of commercialization of Eptinezumab (ALD 403) US sales in 2Q 2020 and EU royalties in 2020. Our estimated 2028 FCF is $495 million and terminal value is 4.5x of 2028 estimated FCF. We layered a probability of clinical success of 90% in addition to a 17% discount rate to arrive at our $11 PT using DCF. For EV/Sales, we apply a 3.5 multiple (based on comps) to discounted 2024 sales to derive our $19 PT. Our weighted average valuation is $15 per share. Our base case scenario valuation assumes unadjusted peak sales of $1.1 bn for Eptinezumab in the U.S. in 2025. Our bull case scenario valuation assumes better than anticipated uptake of Eptinezumab with unadjusted peak sales of $1.3 bn in the U.S. in 2025 and a 4.0x terminal multiple, resulting in a $22 PT." (12/12/2018)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating and $21 PT for ALDR. Monday, AMC, Alder reported cash of $485M, and our model projects the balance sheet to fund operations well into 2020. Questions on the earnings call centered on the eptinezumab market opportunity and commercialization strategy as the fourth CGRP monoclonal to enter the space. We believe that epti’ is in a class all its own as the only IV form and has a differentiated clinical profile that makes it well-positioned to target the highest burden migraine market and a prescriber base that would prefer to use in-office infusion capabilities." (11/6/2018)
Has Alder Biopharmaceuticals been receiving favorable news coverage?
Media coverage about ALDR stock has trended neutral this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alder Biopharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Alder Biopharmaceuticals' key competitors?
Some companies that are related to Alder Biopharmaceuticals include Horizon Pharma (HZNP), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Evotec (EVTCY), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX) and Arena Pharmaceuticals (ARNA).
Who are Alder Biopharmaceuticals' key executives?
Alder Biopharmaceuticals' management team includes the folowing people:
- Dr. John A. Latham, Co-Founder & Chief Scientific Officer (Age 59)
- Mr. Larry K. Benedict, Principal Accounting Officer & Exec. VP (Age 58)
- Ms. Elisabeth A. Sandoval M.B.A., M.B.A, Chief Commercial Officer & Exec. VP of Corp. Strategy (Age 57)
- Dr. Jeffrey T. L. Smith, Managing Director of Alder Biopharmaceuticals Limited (Age 59)
- Mr. Robert W. Azelby, Pres, CEO & Director (Age 51)
Who are Alder Biopharmaceuticals' major shareholders?
Alder Biopharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Samlyn Capital LLC (4.13%), BB Biotech AG (4.05%), Dimensional Fund Advisors LP (1.70%), Bellevue Group AG (1.64%), Pinnacle Associates Ltd. (1.36%) and Massachusetts Financial Services Co. MA (1.10%). Company insiders that own Alder Biopharmaceuticals stock include Jeffrey T L Smith, John A Latham, Mark James Litton and Stephen M Dow. View Institutional Ownership Trends for Alder Biopharmaceuticals.
Which major investors are selling Alder Biopharmaceuticals stock?
ALDR stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Brown Advisory Inc., First Trust Advisors LP, Pinnacle Associates Ltd., Caption Management LLC, MetLife Investment Advisors LLC, Northern Trust Corp and New York State Common Retirement Fund. Company insiders that have sold Alder Biopharmaceuticals company stock in the last year include Jeffrey T L Smith, John A Latham and Mark James Litton. View Insider Buying and Selling for Alder Biopharmaceuticals.
Which major investors are buying Alder Biopharmaceuticals stock?
ALDR stock was bought by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, BB Biotech AG, Millennium Management LLC, Bellevue Group AG, Dimensional Fund Advisors LP, Citigroup Inc., Artal Group S.A. and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for Alder Biopharmaceuticals.
How do I buy shares of Alder Biopharmaceuticals?
Shares of ALDR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alder Biopharmaceuticals' stock price today?
One share of ALDR stock can currently be purchased for approximately $14.32.
How big of a company is Alder Biopharmaceuticals?
Alder Biopharmaceuticals has a market capitalization of $978.44 million and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-288,870,000.00 in net income (profit) each year or ($4.95) on an earnings per share basis. Alder Biopharmaceuticals employs 193 workers across the globe.
What is Alder Biopharmaceuticals' official website?
How can I contact Alder Biopharmaceuticals?
Alder Biopharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected]
MarketBeat Community Rating for Alder Biopharmaceuticals (NASDAQ ALDR)
MarketBeat's community ratings are surveys of what our community members think about Alder Biopharmaceuticals and other stocks. Vote "Outperform" if you believe ALDR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDR will underperform the S&P 500 over the long term. You may vote once every thirty days.
